Sorafenib is a type of medicine used to treat certain kinds of cancer. It works by blocking the growth of cancer cells. It's used for advanced kidney cancer, liver cancer, and thyroid cancer that hasn't responded to other treatments.
Every report comes from a Lived member, sent anonymously.
Have you tried Nexavar (Sorafenib) for Hepatocellular Carcinoma?
Sorafenib, sold under the brand name Nexavar and also available as a generic, is a prescription cancer medicine taken as a tablet. In the US it is approved for three cancers: hepatocellular carcinoma (the most common type of primary liver cancer) when it cannot be removed with surgery; advanced renal cell carcinoma (the most common type of kidney cancer); and differentiated thyroid cancer that has come back or spread, is still growing, and no longer responds to radioactive iodine treatment. In a large trial, sorafenib helped people with advanced liver cancer live longer than a placebo did. Since then, an immunotherapy combination of atezolizumab and bevacizumab has been shown to work better as a first treatment, so for liver cancer sorafenib is now mainly used when immunotherapy combinations are unsuitable, or later in treatment. Its aim in all three cancers is to control the disease and slow its growth, not to cure advanced cancer.
Cells use signaling proteins called kinases as switches that tell them when to grow and divide. Tumors also need a blood supply, and they send out signals that encourage new blood vessels to grow toward them. Sorafenib is a kinase inhibitor that blocks several of these switches at once: some inside the cancer cells themselves, and receptors for VEGF (vascular endothelial growth factor), a key signal for new blood vessel growth. The result is that tumors grow more slowly and receive less support from new blood vessels. In clinical trials this more often held cancer steady than made it shrink; in kidney cancer, for example, few tumors got noticeably smaller, but the cancer took longer to progress. Blocking blood vessel signals also explains why sorafenib can slow the healing of wounds.
Sorafenib tablets are taken by mouth twice a day. They should be taken without food, at least 1 hour before or 2 hours after a meal, because a high-fat meal noticeably reduces how much of the drug the body absorbs. The usual starting dose is the same for all three cancers, and treatment generally continues for as long as it is helping and side effects stay manageable. Dose reductions and short pauses are a common part of treatment. The care team may lower the dose, pause it or stop it because of skin reactions, blood pressure, liver test results or other side effects, so follow the current instructions rather than the original prescription. If a dose is missed, skip it and take the next one at the usual time; do not double up. If too much is taken, call the doctor right away or go to an emergency room.
The most common side effects are diarrhea, tiredness, rash, hair thinning or patchy hair loss, loss of appetite, weight loss, nausea, abdominal pain and infections. A problem called hand-foot skin reaction is especially typical of sorafenib: painful redness, swelling and sometimes blisters on the palms and soles. It and rash usually appear in the first six weeks. Raising it early matters, because soothing skin treatments, short breaks and dose adjustments usually keep it manageable, while a severe reaction can make walking or using the hands painful. High blood pressure is also common, especially early in treatment, which is why it is checked every week for the first six weeks. It is usually controlled with standard blood pressure medicine. Less often, sorafenib causes serious problems, and each has signs that call for contacting the care team right away. Bleeding can show up as vomiting blood or material that looks like coffee grounds, black or bloody stools, pink or brown urine, coughing up blood or unusually heavy periods. Liver injury can cause yellow skin or eyes, dark tea-colored urine, pale stools or pain on the right side of the abdomen. A tear in the stomach or bowel wall is rare; its main sign is severe stomach pain, especially with fever or vomiting. A severe skin reaction, separate from hand-foot skin reaction, causes blistering or peeling skin or blisters in the mouth. Feeling faint, lightheaded or dizzy can signal an abnormal heart rhythm. Chest pain, shortness of breath, a racing or irregular heartbeat, fainting, or new swelling of the legs or abdomen can signal reduced blood flow to the heart or heart failure and need emergency help right away.
Tell the care team and pharmacist about every medicine and supplement you take. Warfarin, a blood thinner, needs particular care: sorafenib can raise the INR (international normalized ratio, a blood test showing how slowly blood clots) and increase bleeding, so INR is checked more closely. Medicines that speed up sorafenib's breakdown in the liver, such as rifampin (an antibiotic used for tuberculosis), can lower its levels and may make it less effective, so they are avoided when possible. The oral antibiotic neomycin also lowers sorafenib levels and is avoided. Sorafenib can lengthen the QT interval, a measure of the heart's electrical recovery between beats seen on an electrocardiogram (ECG). A long QT interval raises the risk of dangerous heart rhythms. For this reason, sorafenib is avoided in people born with long QT syndrome, other medicines that lengthen the QT interval (including some heart rhythm drugs) are avoided where possible, and people at higher risk may have ECGs and blood levels of potassium, magnesium and calcium checked. Sorafenib may harm a developing baby. People who could become pregnant need a pregnancy test before starting and effective birth control during treatment and for 6 months after the last dose; males with partners who are pregnant or could become pregnant should use effective birth control during treatment and for 3 months after. Breastfeeding is avoided during treatment and for 2 weeks after the last dose. Sorafenib may also reduce male fertility. Because it slows wound healing, sorafenib is stopped at least 10 days before planned surgery and restarted only once the wound has healed, and not sooner than 2 weeks after major surgery. In people with thyroid cancer, it can interfere with thyroid hormone treatment, so TSH (thyroid-stimulating hormone) is checked monthly and the thyroid medicine dose may need adjusting.
Sorafenib is usually taken every day for months, and longer if the cancer stays under control and side effects are tolerable. Regular scans show whether the cancer is stable, shrinking or growing; for many people, success means the cancer stops growing for a time rather than disappearing. In the trial that led to its approval for advanced liver cancer, which mostly included people whose liver still worked fairly well, the median survival (the point by which half of people had died) was 10.7 months with sorafenib compared with 7.9 months with a placebo. In thyroid cancer, it nearly doubled the time before the cancer grew (a median of 10.8 versus 5.8 months), but did not clearly lengthen overall survival. These are averages from older trials; individual results vary widely, and newer treatments have changed the options, especially for liver cancer. Side effects tend to be most noticeable in the first weeks. Expect weekly blood pressure checks for the first six weeks and regular blood tests of liver function, along with monthly thyroid tests for thyroid cancer. If the cancer grows, or side effects remain hard to live with even at lower doses, the care team will usually discuss moving to a different treatment.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Nexavar (Sorafenib), what you've noticed, or ask the community a question.